The competition for pulse electric field ablation intensifies, and domestic equipment takes the lead in “opening” in China

In 2022, the number of catheter ablation surgeries in China has approached 290000, with a compound annual growth rate of 14.2%. According to a research report on the Chinese market for cardiac electrophysiological devices, it is expected that by 2024, the number of cardiac electrophysiological surgeries in China will reach 489000, with an annual growth rate of 23.3%. The huge market growth potential has also prompted domestic medical device companies to join the layout.

With the intensification of competition in the global medical device industry, multinational giants are laying out product pipelines that are expected to lead the next decade. Among them, a technology called pulse electric field ablation (PFA) has received much attention in recent years, representing the forefront of current technological development in the field of electrophysiology and is also considered to be the dominant heart ablation technology for the next decade.

Multiple multinational companies entering the market

The domestic market has enormous potential